Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans
Abstract
Substantial progress in understanding the biology of regulatory T cells and their roles in health and disease has been achieved in the past 10 years. This has led to an increasing interest in the possibility of using regulatory T cells as a biological therapy to preserve and restore tolerance to self antigens and alloantigens. Immunotherapy by the adoptive transfer of regulatory T cells may have several advantages over conventional treatments. However, several hurdles have to be overcome before such a therapy can enter clinical practice. This Review summarizes our current knowledge of regulatory T cells, illustrates the ongoing regulatory T-cell-based clinical trials, analyses the strengths and pitfalls of this new therapeutic approach, and highlights the future perspectives.
Cited By (8)
- Epigenetic mechanisms of regulation of FoxP3 expressionBlood · 2009
- T regulatory cells and their counterparts: masters of immune regulationClinical & Experimental Allergy · 2009
- Induction of alloantigen-specific human T regulatory cells by vasoactive intestinal peptideThe Journal of Immunology · 2009
- The kinetics of CD4+Foxp3+ T cell accumulation during a human cutaneous antigen-specific memory response in vivoJournal of Clinical Investigation · 2008
- The role of regulatory T cells in multiple sclerosisNature Clinical Practice Neurology · 2008
- Making sense of regulatory T cell suppressive functionSeminars in Immunology · 2011
- Autoimmune heart diseaseElsevier eBooks · 2022